NED Biosystems Appoints Geoffrey Ling as CEO

NED Biosystems has appointed Geoffrey Ling, MD, PhD, Col. (Ret.), as chief executive officer. A former U.S. government leader of innovation, Dr. Ling is well-known for his ability to identify, advise and direct solutions to overcome global medical challenges. 
 
Dr. Ling currently serves as co-leader of The Brain Health Project, as a professor of neurology, and is an attending neurocritical care physician at Johns Hopkins University and Hospital. He previously served as the founding director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense and as assistant director for Medical Innovation of the Science Division in President Obama’s White House Office of Science and Technology Policy (OSTP). A retired U.S. Army colonel, Dr. Ling proudly served for 27 years during which time he was deployed to Iraq and Afghanistan.
 
“As a visionary and energetic champion of novel approaches to solve unmet medical needs, Geoff will provide an unprecedented level of guidance for our company and will be an incredible asset as we continue the development of our lead therapeutic, NED-170,” said Rebecca Lambert, founder and executive chair of NED Biosystems’ Board. “In moving from Board member to CEO, Geoff brings the strategic leadership and the hands-on innovation management expertise our cancer combination merits.”  
 
“NED-170 represents a major breakthrough in cancer that will potentially benefit all cancer patients – even those in the developing world,” said Dr. Ling. “I am passionate about NED’s mission and believe NED-170’s system biology approach is what has long been missing in the cancer treatment armament. Cancer patients want to effectively treat and manage their disease while enjoying full quality of life. This is NED-170’s promise. I look forward to working with NED’s remarkable team to bring our therapy to market.”